A Phase 4 interventional study of Betamethasone or tacrolimus ointments and Azithromycin in Atopic Dermatitis, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Cairo University · Phase 4, Interventional, and Treatment
The study will evaluate the role of adding azithromycin to topical treatment in patients with mild to moderate atopic dermatitis
1,419 studies on the registry are indexed under Dermatitis, Atopic; 258 are open to participants now.
This study's planned enrollment of 40 is below the median of 83 across 1,125 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Atopic dermatitis patients on topical betamethasone and tacrolimus ointments
Drug: Betamethasone or tacrolimus ointments
Atopic dermatitis treated with azithromycin besides topical betamethasone and tacrolimus ointments
Drug: Betamethasone or tacrolimus ointments · Drug: Azithromycin
Topical treatment will be applied, Betamethasone or tacrolimus ointments
Azithromycin will be combined with topical treatment
Improvement in Eczema Area and Severity Index (EASI)
The primary outcome will be the change in the Eczema Area and Severity Index (EASI) score from baseline to the end of the treatment period. The EASI is a validated clinician-assessed tool that evaluates the severity and extent of atopic dermatitis by assessing erythema, edema/papulation, excoriation, and lichenification across four body regions. Scores range from 0 to 72, with higher scores indicating more severe disease. Outcome variable: Mean change in EASI score from baseline. Assessment time points: Baseline, Week 2, Week 4, Week 8, and end of follow-up. Treatment response: Proportion of patients achieving EASI-50, EASI-75, and EASI-90 (≥50%, ≥75%, and ≥90% improvement from baseline).
Time frame: 3 months
Investigator's Global Assessment (IGA)
The Investigator's Global Assessment will be used to evaluate the overall clinical severity of atopic dermatitis. Scale: 0 = Clear 1. = Almost clear 2. = Mild 3. = Moderate 4. = Severe Outcome variables: Mean change in IGA score. Percentage of patients achieving IGA 0/1 (clear or almost clear).
Time frame: 4 months
Pruritus Severity
Pruritus will be assessed using a 10-cm Visual Analog Scale (VAS) or Numeric Rating Scale (NRS, 0-10). 0 = No itch 10 = Worst imaginable itch Outcome: Mean reduction in pruritus score.
Time frame: 3
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University